Cytokinetics Inc (NASDAQ: CYTK) kicked off on Friday, up 3.00% from the previous trading day, before settling in for the closing price of $47.67. Over the past 52 weeks, CYTK has traded in a range of $30.68-$110.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 12.30% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 3.08%. With a float of $113.59 million, this company’s outstanding shares have now reached $118.01 million.
In an organization with 423 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -2872.48%, operating margin of -16297.79%, and the pretax margin is -17906.24%.
Cytokinetics Inc (CYTK) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 3.75%, while institutional ownership is 113.26%. The most recent insider transaction that took place on Nov 18 ’24, was worth 252,750. In this transaction President & CEO of this company sold 5,000 shares at a rate of $50.55, taking the stock ownership to the 397,456 shares. Before that another transaction happened on Nov 18 ’24, when Company’s Officer proposed sale 5,000 for $50.55, making the entire transaction worth $252,728.
Cytokinetics Inc (CYTK) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.38 earnings per share (EPS), lower than consensus estimate (set at -0.95) by -0.43. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Take a look at Cytokinetics Inc’s (CYTK) current performance indicators. Last quarter, stock had a quick ratio of 9.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1853.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.39, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -5.35 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Let’s dig in a bit further. During the last 5-days, its volume was 1.65 million. That was inferior than the volume of 2.05 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 5.94%. Additionally, its Average True Range was 2.22.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 12.10%, which indicates a significant decrease from 14.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.02% in the past 14 days, which was higher than the 38.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $53.60, while its 200-day Moving Average is $59.38. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $50.14. Second resistance stands at $51.18. The third major resistance level sits at $52.54. If the price goes on to break the first support level at $47.74, it is likely to go to the next support level at $46.37. Assuming the price breaks the second support level, the third support level stands at $45.33.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
The company with the Market Capitalisation of 5.97 billion has total of 118,014K Shares Outstanding. Its annual sales at the moment are 7,530 K in contrast with the sum of -526,240 K annual income. Company’s last quarter sales were recorded 460 K and last quarter income was -160,550 K.
